Lupus Nephritis Plasma

About Lupus Nephritis Plasma

Lupus Nephritis Plasma for Autoimmune Kidney Disease Research

Lupus Nephritis Plasma is collected from IRB-consented donors clinically diagnosed with lupus nephritis and processed within one day of collection to preserve labile analytes such as complement components, cytokines, proteins, and metabolites. Cryopreserved and available in custom aliquot volumes. Research Use Only (RUO).

Disease Mechanism and Why Plasma

• Lupus nephritis is the renal manifestation of systemic lupus erythematosus, an autoimmune disease driven by loss of tolerance to nuclear antigens and by antinuclear and anti-double-stranded DNA autoantibodies.
• Renal injury is initiated by deposition of nucleic acid-containing immune complexes in the glomerulus, followed by complement activation, leukocyte recruitment, and glomerular inflammation. Consumption of complement, with low C3 and C4, accompanies active renal disease.
• Histological class under the ISN/RPS system, from mesangial through proliferative to membranous patterns, determines treatment and prognosis and is the single most important stratifier for interpreting biomarker data.
• Anti-dsDNA titers and complement levels are established, measurable circulating correlates of renal activity, and anti-C1q antibodies have been studied in the same context.
• Many candidate lupus nephritis activity markers are urinary rather than circulating. Plasma is the correct matrix for autoantibody, complement, systemic cytokine, and renal function analyte measurement, and is often paired with urine in study designs.
• Plasma is acellular. This product supports soluble analyte, proteomic, and metabolomic work, not flow cytometry or other cell-based assays.

Donor Stratification Available

• Biopsy-proven ISN/RPS histological class where documented
• Renal disease activity: active nephritis versus remission or low activity
• Degree of proteinuria and estimated glomerular filtration rate category
• Autoantibody and complement status: anti-dsDNA titer, low C3 or C4
• Treatment status: mycophenolate, cyclophosphamide, calcineurin inhibitor, biologic therapy, corticosteroid, or treatment-naive
• Extrarenal SLE manifestations, disease duration, age, sex, and self-reported race/ethnicity
• Matched healthy controls available; SLE donors without renal involvement available as disease controls

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed lupus nephritis donors
• Processed within one day of collection
• Cryopreserved for long-term stability
• IRB-approved protocols and electronic informed consent
• Custom aliquot volumes and anticoagulant options available upon request; paired urine available on request

De-identified Donor Data

• Verified lupus nephritis diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Renal histology class, proteinuria, and renal function values where available
• Additional lupus nephritis-specific metadata available on request

Applications

• Anti-dsDNA and anti-nuclear autoantibody assay development
• Complement activation and immune complex research
• Cytokine, chemokine, and inflammatory mediator profiling
• Plasma proteomics for renal activity and flare-prediction biomarker discovery
• Renal function analyte measurement and kidney injury marker research
• Metabolomic analysis in autoimmune renal disease
• Treatment response and remission-induction biomarker studies
• Disease-state matrix for immunoassay development and validation

Other Lupus Nephritis Specimen Types

• Lupus Nephritis Serum
• Lupus Nephritis Whole Blood
• Lupus Nephritis PBMC
• Lupus Nephritis Leukopak
• Systemic Lupus Erythematosus Plasma

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11-compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Lupus Nephritis Plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse all matrices and disease states, visit our human plasma page.